Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) Director Robert Williamson III purchased 15,000 shares of Perspective Therapeutics stock in a transaction that occurred on Wednesday, November 18th. The stock was purchased at an average price of $0.80 per share, with a total value of $12,000.00. Following the completion of the purchase, the director directly owned 68,473 shares in the company, valued at $54,778.40. This trade represents a 28.05% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Perspective Therapeutics Stock Down 3.4%
Shares of NYSEAMERICAN CATX opened at $0.75 on Friday. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average price is $1.89 and its two-hundred day moving average price is $3.36. Perspective Therapeutics, Inc. has a one year low of $0.73 and a one year high of $6.16.
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. On average, sell-side analysts anticipate that Perspective Therapeutics, Inc. will post -1.01 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several research firms recently commented on CATX. BMO Capital Markets restated an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Royal Bank Of Canada lowered shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $14.00 to $4.00 in a research report on Monday, October 26th. Wedbush reiterated an “outperform” rating and issued a $7.00 price objective (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday, November 10th. William Blair initiated coverage on shares of Perspective Therapeutics in a report on Friday, September 18th. They issued an “outperform” rating for the company. Finally, Piper Sandler cut their price objective on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Nine analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $10.10.
View Our Latest Analysis on Perspective Therapeutics
Institutional Investors Weigh In On Perspective Therapeutics
Large investors have recently added to or reduced their stakes in the stock. Provenance Wealth Advisors LLC bought a new position in Perspective Therapeutics during the 3rd quarter worth $44,000. Auctus Advisors LLC raised its holdings in Perspective Therapeutics by 83.6% in the 3rd quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock valued at $103,000 after acquiring an additional 17,015 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Perspective Therapeutics by 53.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock valued at $168,000 after acquiring an additional 21,150 shares in the last quarter. Taylor & Morgan Wealth Management LLC raised its holdings in Perspective Therapeutics by 127.6% in the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock valued at $225,000 after acquiring an additional 37,000 shares in the last quarter. Finally, Quantinno Capital Management LP bought a new stake in shares of Perspective Therapeutics during the 1st quarter valued at $273,000. Institutional investors and hedge funds own 54.66% of the company’s stock.
Perspective Therapeutics Company Profile
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.
Read More
- Five stocks we like better than Perspective Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
